Chiusura precedente | 0,7650 |
Aperto | 0,8800 |
Denaro | 0,8700 x 0 |
Lettera | 0,9000 x 0 |
Min-Max giorno | 0,7950 - 0,7950 |
Intervallo di 52 settimane | 0,5450 - 1,9300 |
Volume | |
Media Volume | 19 |
Capitalizzazione | 54,822M |
Beta (5 anni mensile) | 1,30 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,7000 |
Prossima data utili | 25 apr 2023 - 01 mag 2023 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 4,89 |
Ruling Has No Impact on NuCana’s Anti-Cancer ProTide PatentsMUNICH, Germany, March 24, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) issued an oral judgement that NuCana’s European Patent 2955190 (the “’190 patent”) is not valid. The TBA reversed the previous decisions of the EPO’s Examination Division which issued NuCana’s ‘190 patent and of the EPO’s O
EDINBURGH, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming investor conferences. Event: Cowen’s 43rd Annual Healthcare Conference Presentation Date: Tuesday, March 7, 2023Presentation Time: 10:30 AM ET Event: Oppenheimer's 33rd Annual Healthcare Conference Presentation Date: Tuesday, March 14, 2023Presentation Time: 12:40 PM ET The pres
EDINBURGH, United Kingdom, Jan. 23, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the matter is